In December 2003, the University of Cambridge UK granted ProteinLogic Ltd a worldwide, and exclusive license to commercially exploit intellectual property owned by Cambridge University UK, Addenbrooke’s NHS Trust (now Cambridge University Hospitals NHS Foundation Trust), and the Medical Research Council (MRC).
The technology was developed by Dr César Milstein and Dr Adrian Woolfson at the MRC Laboratory of Molecular Biology in Cambridge UK. They were subsequently joined by Professor Nick Hales from the Department of Clinical Biochemistry at the University of Cambridge UK. ImmiPrint® diagnostic technology is partly based on the work on monoclonal antibodies, for which Milstein was awarded the Nobel Prize in Medicine and Physiology.
Unlike existing diagnostic systems, which measure the levels of only a single or at most two to three different proteins, ImmiPrint® technology uses high-throughput immunoassays to measure multiple immune system proteins in parallel in body fluids.
Powerful pattern recognition software developed in Cambridge UK is then used to analyse databases of proteomic profiles to generate disease-specific sCD biomarker signatures.
ImmiPrint® technology is a biomarker search and discovery platform relevant to multiple disease types. Individual ImmiPrint® signatures can be used to make diagnostic and other clinical decisions based on the testing of a small volume of a body fluid, such as blood.
The key to the technology is the sCD immune system protein content that ProteinLogic Ltd has identified and protected through the filing of international patents.
By focusing on a discrete, logical and finite set of diagnostic sCD biomarkers, ProteinLogic Ltd has provided a practical solution to the ‘content problem’, significantly reducing the complexity associated with the proteomic analysis of complex body fluid solutions and the identification of sensitive and specific biomarkers.
ImmiPrint® technology is unique as it enables the same set of immune system sCD biomarkers to be used for all disease types. Each disease is characterized by its own specific sCD proteomic barcode. ImmiPrint® technology provides a universal search engine for the rapid, efficient and cost-effective discovery of diagnostic sCD biomarker signatures.